Integrative transcriptomics in smoking related lung diseases by Kusko, Rebecca
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Integrative transcriptomics in
smoking related lung diseases
https://hdl.handle.net/2144/15452
Boston University
	  BOSTON UNIVERSITY 
 












INTEGRATIVE TRANSCRIPTOMICS IN SMOKING  
 





















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 








































© 2015 by 
 REBECCA KUSKO 
 All rights reserved  






First Reader _________________________________________________________ 
 Avrum Spira, M.D., M.Sc. 
 Professor of Medicine 
 
 
Second Reader _________________________________________________________ 
 Yuriy Alekseyev, Ph.D. 
 Research Associate Professor 
 
	  	   iv 
ACKNOWLEDGMENTS	  
I would like to take this opportunity to thank everyone who inspired and supported me 
throughout my thesis.  Firstly, I would like to thank my thesis adviser Avrum Spira for 
bringing me into the lab and giving me room to grow scientifically and personally.  I am 
also sincerely grateful to my committee chair Monty Montano for mentoring me and 
pushing me to achieve.  The rest of my thesis committee also provided an incredible 
amount of guidance throughout my journey to complete my PhD for which I am very 
grateful. 
 
Next I would like to thank the members of the Spira-Lenburg lab for all the helpful 
discussions, reviews of my work, pleasant conversations, and adventures.   
 
I am eternally grateful to my family, especially my parents who tirelessly pushed me to 
believe in myself and to continue to try harder.  I am also thankful to my entire family, 
both the family that has been supportive throughout my entire life and all the new family 
that I gained more recently.   
 
Lastly I greatly appreciate all my friends and Arthur who played a critical role in keeping 
me sane and helping me to see the big picture.  My capacity to endure comes from the 
support of these people. 
  
	  	   v 
INTEGRATIVE TRANSCRIPTOMICS IN SMOKING 
RELATED LUNG DISEASES 
REBECCA KUSKO 
Boston University School of Medicine, 2015 
Major Professor: Avrum Spira, M.D., M.Sc., Professor of Medicine 
 
ABSTRACT 
Chronic lung diseases including Chronic Obstructive Pulmonary Disease 
(COPD), Idiopathic Pulmonary Fibrosis (IPF) and lung cancer are major causes of 
morbidity and mortality in the United States due to high incidence and limited therapeutic 
options. In order to address this critical issue, I have leveraged RNA sequencing and 
integrative genomics to define disease-associated transcriptomic changes which could be 
potentially targeted to lead to new therapeutics.  
We sequenced the lung transcriptome of subjects with IPF (n=19), emphysema 
(n=19, a subtype of COPD), or neither (n=20). The expression levels of 1770 genes 
differed between IPF and control lung, and 220 genes differed between emphysema and 
control lung (p<0.001). Upregulated genes in both emphysema and IPF were enriched for 
the p53/hypoxia pathway. These results were validated by immunohistochemistry of 
select p53/hypoxia proteins and by GSEA analysis of independent expression microarray 
experiments. To identify regulatory events, I constructed an integrative miRNA target 
prediction and anticorrelation miRNA-mRNA network, which highlighted several 
miRNA whose expression levels were the opposite of genes differentially expressed in 
both IPF and emphysema. MiR-96 was a highly connected hub in this network and was 
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subsequently overexpressed in cell lines to validate several potential regulatory 
connections. 
Building upon these successful experiments, I next sought to define gene 
expression changes and the miRNA-mRNA regulatory network in never smoker lung 
cancer. Large and small RNA was sequenced from matched lung adenocarcinoma tumor 
and adjacent normal lung tissue obtained from 22 subjects (8 never, 14 current and 
former smokers). I identified 120 genes whose expression was modified uniquely in 
never smoker lung tumors. Using a repository of gene-expression profiles associated with 
small bioactive molecules, several compounds which counter the never smoker tumor 
signature were identified in silico. Leveraging differential expression information, I again 
constructed an mRNA-miRNA regulatory network, and subsequently identified a 
potential never smoker oncomir has-mir-424 and its transcription factor target FOXP2.  
In this thesis, I have identified genes, pathways and the miRNA-mRNA 
regulatory network that is altered in COPD, IPF, and lung adenocarcinoma among never 
smokers. My findings may ultimately lead to improved treatment options by identifying 
targetable pathways, regulators, and therapeutic drug candidates. 
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Smoking Associated Lung Disease Clinical Overview 
Smoking associated lung diseases such as Chronic Obstructive Pulmonary 
Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and lung cancer are major causes 
of morbidity and mortality in the United States. Currently, they cause an estimated 
300,000 deaths per year (158,318 from lung cancer, 134,676 from COPD, and 40,000 
from IPF)1,2. This is likely an underestimate as COPD and IPF are frequently 
underdiagnosed clinically3. Lung cancer is the leading cause of cancer related death in 
men and women, causing more mortalities than pancreas, breast, and colorectal cancer 
combined4. Adding to the burden of smoking related lung diseases, COPD is the third 
leading cause of mortality in the United States, after heart disease and cancer. While IPF 
represents a much smaller disease burden, the incidence of this disease has doubled in the 
past decade5.   
All three smoking related lung diseases carry a large mortality burden because 
lung cancer has an exceptionally low 5 year survival rate (16.6%), and a treatment is not 
yet clinically available which halts the underlying pathogenesis of COPD or IPF6.  
Despite significant funding for pulmonary research in past decades, these diseases are 
persistently major public health problems. All three diseases have differing clinical 
pathology, but are associated with shared environmental factors such as cigarette 
smoking and air pollution7–9. 
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Chronic Obstructive Pulmonary Disease 
COPD limits a patient’s pulmonary function and is considered a progressive 
disease, as severity increases with time. Patients with COPD will experience symptoms 
such as shortness of breath, wheezing, and productive cough. More than eighty percent of 
COPD patients are current or former smokers, making COPD a strongly smoking 
associated disease. Although it has been known since the 1964 Surgeon General’s report 
on smoking that cigarette smoke causes COPD, the molecular processes underlying this 
connection remain unclear10,11.  
COPD is a disease constellation contains two disease subtypes: 1. chronic 
bronchitis, defined as “the presence of chronic productive cough for at least 3 months in 
two consecutive years, after excluding other causes of chronic cough.” or 2. emphysema, 
defined as “a condition of the lung characterized by abnormal, permanent enlargement of 
airspaces distal to the terminal bronchiole, accompanied by the destruction of their walls, 
and without obvious fibrosis.9” Patients can be afflicted with one, the other, or both of 
these subtypes.  
Patients diagnosed with COPD have airflow obstruction which is not permanently 
reversible with bronchodilator administration12,13. In order to arrive at this diagnosis or to 
classify COPD, physicians use clinical features such as forced expiratory volume in 1 
second (FEV1, measured through spirometry), forced vital capacity (FVC, measured 
through spirometry), FEV1/FVC ratio, and the GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) staging process 12. However, these classification systems have 
limited clinical utility, as they do not reflect future rate of airway thickening or 
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emphysematous destruction, histopathology, recommended treatment course, or other 
clinical variables.  
Information about the clinical pathogenesis of COPD remains limited. It has long 
been observed that tobacco abstinence does not reverse or cure COPD, suggesting 
permanent and irreversible molecular damage. Moreover it has been observed that COPD 
is highly smoking associated but does not occur in all smokers, suggesting a shared 
genetic and environmental component.  Specifically, some literature evidence suggests 
that the emphysema subtype is related to a mis-balance between elastin and anti-elastin 
production, causing the alveolar destruction phenotype observed in patients14. Adding 
support to this hypothesis, it is known that pro-inflammatory elastase producing 
macrophages are present at higher levels in the lungs of smokers15,16. Additional studies, 
including mouse work, have since implicated a complex immune mediated 
inflammation17–19. Most recently, selective apoptosis of structural cells are under 
suspicion for leading to the emphysema phenotype as well20. Despite these recent 
advances, the fact remains that no drug or treatment has been discovered that can target 
the molecular pathogenesis of emphysema, suggesting an urgent clinical need for 
improved understanding of the molecular mechanisms of disease development and 
progression.  
Idiopathic Pulmonary Fibrosis 
IPF is a devastating disease characterized by an overabundance of scar tissue in 
the parenchyma of the lung, which leads to shortness of breath, dry cough, weight loss, 
finger clubbing, and fatigue. This fibrosis often occurs in a heterogeneous manner, with 
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select portions of the lung being effected and others not. Like COPD, IPF is a progressive 
disease, which worsens in a patient over time.  
 While both COPD and IPF are smoking associated, the molecular etiology of IPF 
is much more poorly understood and is under active investigation. Both genetics and the 
environment are guilty parties for driving this disease21–25.  Based on observations of the 
pathology of IPF, including alveolar remodeling and invasion of fibroblasts, abnormal 
wound healing has been implicated26. When injured, the lung normally goes through a 
number of stages, one of which is fibrosis. Others have suggested that in IPF, wound 
healing becomes “stuck” in fibrosis and never progresses to the next stage24. While the 
final phenotype is very different, IPF does have certain molecular steps in common with 
emphysema, such as remodeling21,22. It is known that the fibrosis is driven specifically by 
myofibroblasts, which produce an excess of extracellular matrix materials which destroys 
the structure and function of the lung27. It is also hypothesized that abnormal epithelial 
cell activation could lead to IPF, in addition to wound healing28.  
IPF is diagnosed using high resolution CT imaging together with a surgical lung 
biopsy29. In patients with IPF, CT scans will reveal usual interstitial pneumonia (UIP) 
and/or honeycombing, where large lined air spaces form. Interestingly, it has been 
observed that some patients have variable emphysema and IPF across the lung30. Science 
has yet to prove whether these are distinct diseases occurring together in the same patient 
or the same underlying disease manifesting itself with heterogeneous phenotypes 




Lung cancer remains the leading cause of cancer-related death in the United States and 
worldwide6. While it is possible to cure lung cancer in a low percentage of patients, this 
disease remains a major cause of morbidity and mortality globally because of a lack of 
early detection and effective treatment options. Patients with lung cancer can experience 
fatigue, persistent cough, increased sputum production, cachexia, and shortness of breath.  
Lung cancer is normally diagnosed first with a CT or PET scan to discover the presence 
of a suspicious nodule, followed by bronchoscopy and/or fine needle biopsy to confirm 
the presence or absence of cancerous cells.   
Although lung cancer is often thought of as a smoker’s disease, 25% of all lung 
cancer patients worldwide are lifelong nonsmokers31. Lung cancer can be split into 
various subtypes. Adenocarcinoma is the most prevalent (40% of lung cancer cases) and 
occurs in the periphery of the lung32. Lung Adenocarcinoma arises from mucus secreting 
epithelial cells that line the airways in the lung. This is the most common form of lung 
cancer to occur in never smokers, and also occurs in current or former smokers. Studies 
suggest exposures (such as secondhand smoke33–36, indoor cooking fumes37–39, 
asbestos40–43, radon44,45, hormones46–50), previous IPF diagnosis51–53, and genetics54,55 as 
factors that can cause lung cancer to occur in never smokers while smoking remains the 
leading factor for lung cancer in current and former smokers.  
Recent studies have described genetic56,57 and genomic57,58 differences between 
never smoker and ever smoker lung tumors. From the mutational perspective, it has been 
observed that there is a higher p5357 and  KRAS59–61 mutation risk in active smokers and 
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a higher EGFR mutation and EML4-ALK fusion62 risk in never smokers. Relatedly, it 
has also been observed that ever and never smokers respond differently to therapy63,64. 
Moreover, the seminal observation that EGFR mutations are more prevalent in never 
smoker lung tumors56 has caused a shift in lung cancer treatment through the use of 
EGFR inhibitor drugs63,64.  Specifically, gefitinib and erlotinib are more effective in 
patients with mutations in the tyrosine kinase domain of EGFR65. Since the discovery of 
the EML4-ALK fusion (more common in never smoker lung adenocarcinoma), it has 
been shown that patients with this fusion respond well to crizotinib66,67.   
While all lung adenocarcinoma demonstrate chromosomal instability, one study 
observed that never smoker tumors as compared to ever smoker tumors tend to have 16p 
gains at a higher frequency68. In addition, never smoker lung adenocarcinoma has unique 
methylation aberrations, such as hypermethylation of the promoters of hMLH1 and 
hMSH269. 	  
Despite these recent advances, lung cancer remains a leading cause of cancer 
related deaths in never smokers, and the molecular drivers within the never smoker lung 
tumor remain unclear. The above evidence supports the hypothesis that never smokers 
and ever smokers experience different molecular processes and events which drive the 
same tumor subtype. Thus, characterizing never smoker-specific molecular alterations in 
lung adenocarcinoma might be leveraged to identify processes that could be targeted by 
new therapeutics and existing compounds that could be repurposed to treat this disease. 
In summary, science has yet to prove conclusively that lung adenocarcinoma 
arises through distinct molecular processes in never smokers as compared to ever 
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smokers, and that these differing mechanisms of carcinogenesis require distinct therapy. 
Thus, understanding the molecular processes that contribute to lung carcinogenesis 
specifically in lifelong nonsmokers would allow us to identify regulators that might be 
targeted for therapy, and existing therapeutics that might be repurposed to treat never 
smoker lung adenocarcinoma. 
High-Throughput Transcriptomics in COPD, IPF, and Lung Cancer 
Microarray Studies 
To date, there have been a number of microarray studies reported in COPD, IPF, 
and lung cancer. At the time, these studies represented major advances in the field as 
microarrays allow for translating the protein coding disease transcriptome. Broadly 
speaking, microarray technologies have generated hypotheses about which pathways 
could be important drivers for COPD, IPF, and lung cancer.  
In the COPD space, a handful of transcriptomic gene expression studies have 
described genes associated with COPD70–75. However, there was little overlap in the exact 
genes reported by these studies76.  More recent work using enrichment-based methods 
such as Gene Set Enrichment Analysis (GSEA)77 has shown that there is more overlap in 
underlying pathways and gene ontology between these datasets than initially perceived, 
such as an overlap in cell adhesion pathways76. Since this analysis was done, several new 
microarray studies have come out and implicated additional pathways, such as TGF-β78, 
WNT79, and inflammation80.  
Although microarray studies in COPD are limited, microarray studies in IPF are 
even more so. Also unlike COPD, publications in the IPF space have converged around a 
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set of pathways. Two gene expression studies comparing normal lung to IPF both 
reported perturbations in the extracellular matrix regulatory pathway81.  A third 
microarray study has been reported but focused on a single differentially expressed gene 
(osteoporin). The authors profiled 13 IPF samples and 11 controls and reported that the 
osteoporin gene was the most upregulated gene in IPF samples as compared to control82.  
In the lung cancer space, a large number of gene expression studies have been 
reported83, but only one group has published array studies in the never smoker lung 
cancer space. Landi et al.84 profiled mRNA expression in 20 never smokers, 26 former 
smokers, and 28 current smokers. In this publication, the authors identify genes 
differentially expressed between the ever smoker versus never smoker tumor and ever 
smoker vs. never smoker adjacent normal. They found that the smoker tumors tend to 
upregulate mitotic spindle formation genes more than the never smoker tumors. The same 
group later profiled miRNA expression in a similar cohort but did not find any smoking 
associated changes in miRNA expression, perhaps due to the low number of never 
smoker patients in the study85. 
RNAseq Studies 
As RNAseq is a relatively new platform and only recently has become more 
accessible in terms of cost, very limited studies using RNAseq have been reported in IPF, 
and COPD. To date, no studies have been reported which sequence COPD samples. One 
study with 3 IPF samples and 3 control samples observed IPF associated changes in 
splicing of senescence and oxidative stress genes86.  
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In never smoker lung adenocarcinoma, multiple publications have reported 
RNAseq studies that have contributed to the hypothesis that never smoker lung 
adenocarcinoma is a molecularly unique disease. One study compared tumor to adjacent 
normal tissue in never smokers, and based on mutational and transcriptomic evidence 
implicated cell proliferation pathways87. However, this study lacked ever smokers as a 
control so it is unclear if their result is unique to never smokers. Another study reported 
transcriptome and whole genome sequencing in 6 never smoker and 11 ever smokers 
with lung adenocarcinoma. The tumors of smokers overall had more mutations, a 
different frequency of point mutations, and were more likely to express the gene 
containing a mutation88. These results greatly supports the hypothesis that never smoker 
lung cancer is a unique molecular entity, although the transcriptomic data was only used 
to support genomic data and was not analyzed independently. 
Computational Approaches 
RNAseq and Microarrays 
The technology of gene expression microarrays has enabled scientists in many 
fields to rapidly and inexpensively profile the expression of protein coding genes. Gene 
expression arrays contain “probes”, which are short DNA sequences that will bind to a 
corresponding protein coding gene transcript after conversion to cDNA. The intensity of 
fluorescence after imaging corresponds to the expression level of a gene. The intensity 
data is typically processed via Robust Multichip Average (RMA), which performs 
background correction, log2 transformation, and quantile normalization prior to 
analysis89. Microarray data has the advantage of being very fast to process, and having a 
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very small memory and storage footprint. However, microarray technology is 
fundamentally limited by two factors: 1. only transcriptomic events with a corresponding 
probe will be profiled and 2. because array data is measured by intensity, the dynamic 
range measurement capabilities are small.  
Recently next generation sequencing technology has developed, improved, and 
become cost effective for transcriptomic profiling. With this technology, isolated RNA is 
built into libraries, which are typically sequenced using reversible terminator chemistry, 
which emits a color depending on which nucleotide binds to the cDNA. Since RNA 
sequencing (RNAseq) is not limited to a specific probe set, it has enabled researchers to 
characterize more exotic members of the transcriptomic zoo, such as microRNAs 
(miRNAs), long noncoding RNAs (lncRNAs), and pseudogenes. Originally thought to be 
junk90, these noncoding RNAs are now known to be highly important in regulating gene 
expression in development, cancer, and a spectrum of other states of health and disease91–
94. Out of noncoding regulatory RNAs, microRNAs (miRNAs) are the best characterized. 
These small RNAs, only 22nt long, bind to the 3’UTR of protein coding genes using a 
specific sequence95.  Binding of the miRNA blocks transcription and/or causes the RNA 
sequence to be degraded, thus stopping the message96. LncRNAs function through a 
much more complicated and less characterized mechanism by modifying chromatin97, 
and/or positively regulating transcription initiation98. In the future, “lncRNA” will likely 
be regarded as a constellation term, as different lncRNAs appear to have different 
functions. Even today, pseudogenes are thought by some to be “junk” expression. A 
pseudogene is a copy of a protein coding gene which has certain mutations that prevent it 
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from being translated into a protein. It has been observed that when expression levels of a 
pseudogene are increased, expression levels of the corresponding protein coding gene are 
increased too99. Since both the full protein coding gene and both the pseudogene have 
very similar 3’ UTR regions, it has been hypothesized that the pseudogene may act as a 
molecular sponge which can “sop up” miRNAs100. Once a miRNA has bound to its 
target, it is not re-used elsewhere for further repression. Thus if a miRNA “finds” a 
pseudogene first it will not be able to target the protein coding version of the gene. To 
sum up, the RNAseq technological revolution has enabled us to posit braver and bolder 
interrogations into the disease transcriptome.  
Data processing for RNAseq is much more complicated than for gene expression 
arrays. Images from the sequencer are processed into “reads”, which represent strings of 
nucleotides called by the sequencing experiment. To determine which genes are 
responsible for generating the observed reads, alignment must be done. Since the 
transcriptome has a gapped structure due to alternative splicing, special aligners such as 
Tophat101,102 and RNAstar103 must be used. After alignment, expression levels can be 
quantified by calculating counts per gene/transcript and then normalizing with tools like 
RSEM104 or with a method which integrates counting and normalizing such as 
Cufflinks102. While RNAseq has the advantage of being able to profile a wider pool of 
RNA and detect changes in a wider range, it is much more memory, time, and storage 




Usually the purpose of a microarray or RNAseq experiment is to find changes in 
the transcriptome that associate with disease condition or phenotype. For log2 normalized 
gene expression array data or log normalized RNAseq data, differentially expressed 
genes or transcripts can be identified by fitting each gene or transcript individually to a 
model. For this approach to work, there must be sufficient sample size and the data must 
be normally distributed. If these conditions are met, a linear model is constructed 
including both the parameter of interest or an interaction of parameters of interest, as well 
as covariates that may also influence the transcriptome. For paired study designs, subject 
specific effects are accounted for with a random effect term. Each linear model produces 
a p-value for each gene or transcript, which is the chance that the observed difference in 
the means of two groups being compared due to chance.  
Network Construction 
Thanks to advances in RNA sequencing technologies, it is now possible to profile 
both mRNA and regulatory noncoding RNA, such as miRNA. In order to understand and 
characterize the interplay between these two types of RNA, networking approaches have 
been developed. Specifically, these algorithms predict which mRNAs will be targeted by 
which miRNAs based on seed sequence, flanking sequences, genomic context, binding 
energy and conservation105–108. Using this prior information, a static directional network 
can be constructed of predicted transcriptomic regulation, where each node is a miRNA 
or mRNA and each edge is a regulatory event. 
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Since it is known that miRNAs and lncRNAs regulate mRNAs, it is possible to 
build a regulatory association network using expression data from gene expression arrays 
or RNAseq. Calculating a correlation coefficient between mRNAs and regulatory RNAs 
of interest represents an easy and intuitive way of constructing this kind of network. This 
integrated network has RNAs as hubs and directed correlation as edges and is driven by 
two kinds of information. For miRNAs, it is much more interesting to look at negative 
correlations, as miRNAs should have opposite expression changes from the genes that 
they regulate. On the other hand, it is much more interesting to look at positively 
correlated lncRNAs, since lncRNAs usually regulate gene expression in a positive or 
enhancing manner.  
By performing large and small RNA profiling on COPD, IPF, and lung cancer 
samples we are empowered to study the transcriptome in an unbiased manner. On first 
pass observation these three diseases seem very different, as they have different 
pathology and physical manifestations. However, all three diseases are smoking related 
and all three diseases lack satisfactory treatment options. One approach to move towards 
improved therapeutics is to supplement the understanding of molecular pathogenesis. 
COPD, IPF, and lung cancer are all smoking associated but not all smokers are diagnosed 
with COPD, IPF, and/or lung cancer, this suggests that these three diseases are regulated 
by both genetics and environmental factors. Given that the transcriptome represents 
readout of the interaction between genes and environment in a patient, the single 
nucleotide resolution of RNA sequencing represents the ideal platform to study these 
three diseases.  
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Integrated Genomics Approach Reveals Convergent Transcriptomic and Network 
Perturbations Underlying COPD and IPF 
Background and Introduction 
Chronic lung diseases affect a large portion of the US population and account for over 
100,000 deaths per year3. The majority of these deaths can be attributed to chronic 
obstructive pulmonary disease (COPD), a frequently occurring smoking induced lung 
disease. A second major contributor to this high mortality rate is idiopathic pulmonary 
fibrosis (IPF), a fibrotic smoking associated lung disease with a nearly 100% fatality rate 
which results in more than 15,000 deaths annually27. COPD is defined by the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) as a disease state characterized 
by exposure resulting in irreversible airflow limitation12, and is thought to result from 
recruitment of inflammatory cells in response cigarette smoke. A subset of patients (those 
with COPD subtype emphysema) experience ECM protein and elastin destruction, 
alveolar cell apoptosis, and/or repair failure, which ultimately causes emphysematous 
airsac enlargement. Conversely, IPF has a very different physical phenotype from 
emphysema and is characterized by the findings of usual interstitial pneumonia (UIP), 
including the presence of inflammatory fibrotic patchy foci, excessive ECM activity and 
abnormal remodeling27.  
The recent development of high throughput transcript profiling has allowed 
investigators to discover mechanisms underlying human diseases. In chronic lung 
disease, limited studies have been reported in COPD 70–73 or IPF 81,82,109,110 and studies of 
miRNA expression in COPD 79,111 or IPF 112,113 remain underdeveloped. Despite having 
common risk factors such as cigarette smoking, no studies to date have directly queried if 
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synergistic pathways exist in IPF and COPD. Recent publications hypothesize that 
parallel pathways may be at play in the development of these two chronic lung diseases 
and that direct comparisons of underlying disease biology may be informative21. In this 
study I examined IPF, COPD and normal lung tissue profiled together, with the intent to 
verify this hypothesis by identifying convergent transcriptional regulatory networks in 
COPD and IPF by leveraging integrative computational and functional transcriptomic 
approaches. 
We performed mRNA sequencing and miRNA profiling using microarrays on 89 
lung tissue samples from subjects with IPF, COPD, or without either disease. Samples 
were obtained through the NHLBI Lung Tissue Research Consortium (LTRC) as part of 
the Lung Genomic Research Consortium (LGRC). To glean disease-associated alterations 
in gene expression, we sequenced the lung transcriptome of each subject and identified 
molecular alterations shared by both chronic lung diseases. The p53/hypoxia pathway 
was up-regulated in both COPD and IPF compared to histologically normal controls, 
which was validated using a different gene expression technology in an independent 
sample cohort. My work provides the first RNA-seq study of chronic lung injury as a 
response to cigarette smoke as represented by both COPD and IPF. The overall study 
design and findings provide vision into a shared chronic lung disease response and 





Characteristics of Study Population and Samples Collected 
 All lung samples were obtained from the Lung Tissue Research Consortium (LTRC) via 
the Lung Genomics Research Consortium (LGRC), both financed by the National Heart, 
Lung, and Blood Institute (NHLBI). In addition to tissue samples, the LTRC provided 
patient clinical information such as pulmonary functions, demographics, imaging results, 
pathology and clinical diagnoses.  Seventy-five of the eighty-seven samples which 
exhibited distinct phenotypes of emphysema, COPD without emphysema, IPF or normal 
histology controls were deemed eligible for analysis (Table 1).  Samples with 
intermediate percent emphysema were excluded from analysis.   Samples were batched 
for sequencing and emphasis was placed on balancing age, smoking history, and gender 
across all batches. Institutional Review Boards approved all studies at participating 
collection and research institutions and all patients signed informed consent.  
 
 
Control IPF COPD (Emphysema >= 30%) 
COPD 
(Emphysema < 10%) 
Numbers 20 19 19 17 
Age 63.3 +/- 10.0 (0) 64.0 +/- 9.7 (0) 56.3 +/- 8.7 (0) 68.4 +/- 10.4 (0) * 
Sex 11 M, 9 F (0) 15 M, 4F (0) 10 M, 9 F (0) 12 M, 5 F (0) 
Pack Years 27.3 +/- 22.6 (4) 31.24 +/- 23.4 (2) 47.9 +/- 27.4 (1) 50.7 +/- 20.4 (2) 
Percent 




1 Current, 14 
Former, 2 Never 
(2) 
17 Former, 2 
Never (0) 18 Former, 1 Never (0) 15 Former (2) 
Table 1: Demographic Information of Samples Used: * = Significant with p < 0.05, *** = 
Significant with p < 0.001, (#) = missing demographics. 
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Fig. 1: Quality Score Across All Bases in One Sample. Blue line = the mean 
quality, Red line = median value, Yellow box = inter-quartile range (25-
75%), Upper and lower whiskers = 10% and 90%. 
	  




Each sample yielded approximately thirty million 75 nucleotide (nt) high quality 
paired-end reads (Figs. 1 and 2), and, on average, 28 million of these reads aligned to 
human genome build 19 using conservative alignment parameters. Specifically, 85.9% ± 
6.9% of reads aligned to the genome, and 81.4% ± 3.1% aligned uniquely. Of the aligned 
reads, 90.3% ± 4.8% were aligned as paired ends (of which 88.7% ± 3.8% were properly 
paired), and 9.04% ± 4.8% were aligned as singletons. From these statistics I concluded 
that the RNA-seq data obtained from the LTRC tissue samples were of high quality. 
	    
	  
Fig. 3. Differentially Expressed Genes. Red indicates higher relative expression, blue indicates 
lower relative expression. A) Top 300 genes differentially expressed in emphysema vs. control B) 
Top 300 genes differentially expressed in IPF vs. control (pval<0.005). 
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Emphysema and IPF Differential Expression 
I identified 2490 genes significantly differentially expressed (DE) between IPF and 
control subjects, and 337 genes DE between emphysema versus control subjects (P- 
value<0.005, 55 IPF genes and 53 emphysema genes expected by chance, Fig. 3). The 
number of genes differentially expressed between subjects with non-emphysema COPD 
and histologically normal controls at the same p-value threshold is less than by chance. 
These results were validated using gene expression microarrays run at a different 
university on the same 75 samples.  The t-statistics were significantly correlated between 
RNAseq and gene expression microarrays (emphysema versus control R=.75 (Fig. 4A), 




Fig. 4: T-statistic between Gene Expression Arrays and RNAseq. A) Correlation of t-statistic of 








Fig. 5: Differential Expression in Emphysema and IPF.  A) scatter plot showing correlation 
between emphysema vs. control (y axis) and IPF vs. control (x axis) t-statistic B) Genes which 
are commonly perturbed in emphysema and IPF.  Red is higher relative expression, blue is 
lower relative expression. C) IHC of key p53 related genes. Black arrows = epithelial cells, 




Strikingly, the genes that distinguished IPF or emphysema from histologically normal 
controls revealed that, while not necessarily similar in magnitude, the overall change in 
gene-expression is concordant as shown in a scatter plot of all genes (Fig. 5A).  
Moreover, it was discovered that 214 genes shared statistically significant changes in 
expression between disease and normal histology controls, which can be seen in the 
heatmap (Fig. 5B). These common molecular alterations were significantly enriched for 
genes in the KEGG p53 pathway, Biocarta p53/Hypoxia pathway, Gene Ontology 
epidermis development, and other biological processes outlined in Table 2.  
 
 
Up in Emphysema and IPF Down in Emphysema and IPF 
Biocarta p53/Hypoxia Biocarta Myosin 
KEGG Alanine Metabolism Biocarta Par1 
KEGG Autoimmune Thyroid KEGG Endocytosis 
KEGG p53 KEGG Long Term Potentiation 
KEGG Ribosome GO Anatomical Morphogenesis 
GO Epidermis Development GO Endocytosis 
GO Tissue Development  
Table 2: Functional Enrichment of Shared Emphysema and IPF Genes. 
GSEA of Biocarta, KEGG, and GO gene sets were used against ranked lists 
of Emphysema vs. Control and IPF vs. Control.  Results included are those 
with pval < .05 and concordance in the same direction.   
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An identical analysis was performed on gene expression from a non-overlapping, 
independent cohort of lung tissue samples obtained from the LTRC (Emphysema N=34, 
control N=77, IPF N=82, Table 3) and profiled using microarrays run at the University of 
Pittsburgh.  Samples were selected based on available clinical data, which was limited for 
certain patients. This analysis confirmed the up-regulation of the p53/hypoxia pathway in 
genes that distinguished emphysema or IPF from normal histology controls. Gene Set 
Enrichment Analysis (GSEA)77 corroborated significant enrichment of the KEGG p53 
and Biocarta p53/hypoxia leading edge from GSEA of the primary cohort among genes 
up-regulated in emphysema or IPF tissues compared to histologically normal controls (p-
value < 0.001 , Fig. 6). Since cell type differences were a concern, we used 
immunohistochemistry to confirm the location of select differentially expressed genes in 
the p53 pathway in control, Emphysema, and IPF samples (N=5 for each). HIF1A, 
MDM2, and NFKBIB were all found to be expressed in the airway epithelium, 
suggesting that this is not a cell type effect (Fig. 3C). 
	   IPF	   COPD	   Control	  
#	  of	  samples	   77	   34	   82	  
Age	   64.4	  ±	  8.7	   60.6	  ±	  9.5	   63.8	  ±	  11.9	  
Sex	   54	  M,	  23	  F	   15	  M,	  19	  F	   35	  M,	  47	  F	  
Race	  
69	  CAU,	  2	  AFA,	  	  2	  ASN,	  1	  OTH	  (3)	   33	  CAU,	  1	  AFA	   76	  CAU,	  1	  HIS,	  	  1	  AFA,	  3	  ASN,	  	  1	  OTH	  
Smoking	  status	  
2	  Current,	  	  42	  Former,	  	  29	  Never	  (4)	   2	  Current,	  	  32	  Former	   1	  Current,	  	  43	  Former,	  	  29	  Never	  (9)	  
Pack	  years	   24	  ±	  18	  (33)	   51	  ±	  27	   37	  ±	  32	  (38)	  
%	  DLCO	   50	  ±	  17	  (10)	   36	  ±	  14	  (2)	   84	  ±	  15	  (9)	  
FEV1%	  predicted	   74.5	  ±	  14.3	  (51)	   31.6	  ±	  12.7	  (4)	   100.0	  ±	  13.5	  (24)	  
%	  emphysema	   0.9	  ±	  1.6	  (63)	   36.6	  ±	  9.9	  (21)	   0.6	  ±	  0.9	  (71)	  




miRNA Regulation of Shared Emphysema and IPF Differential Expression 
Integrating mRNA-Seq and miRNA microarray expression data on the same samples 
uncovered additional insights into the transcriptomic regulation of the p53/hypoxia 
pathway in emphysema and IPF. Using miRconnX114 I created a data-driven and prior-
knowledge-based gene/miRNA regulatory network. Initially, I constructed a regulatory 
network using genes differentially expressed (p < 0.05) in the same direction in both 
emphysema and IPF to explore shared regulatory mechanisms between the two diseases 
(http://mirconnx.csb.pitt.edu/job_results?job_id=example10103). The network contains 
15 miRNA, including miR-96, and 31 genes. We created two additional networks by 
submitting Emphysema vs. control genes 
(http://mirconnx.csb.pitt.edu/job_results?job_id=example10102) and IPF vs. control 
genes (Fig. 7, or http://mirconnx.csb.pitt.edu/job_results?job_id=example10101) with the 
	  
Fig. 6: Leading Edge of p53/Hypoxia Genes in Independent Sample Set. A) Ranked list was IPF 
vs. control B) Ranked list was emphysema vs. control. 
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same p-value cutoff. Both of these networks featured miR-96 as the most connected 
miRNA, suggesting that it plays an important regulatory role.  
 
Fig. 7: Shared Emphysema and IPF miRNA Regulatory Network. Regulatory miRNA-mRNA 
network showing regulation in both diseases. Red lines indicate direction of repression. Bold red 
lines indicate interactions that were selected and validated by PCR.  IPF mRNA = mRNA 
differentially expressed in IPF vs. control.  Emp mRNA = mRNA differentially expressed in 




We validated the up-regulation of miR-96 in the emphysema and IPF regulatory 
network by qRT-PCR. Overexpression of miR-96 in fibroblasts and epithelial cells 
repressed the expression of glutamate transporter SCL1A1 and BTK inhibitor SH3BP5 
(Fig. 8). These genes are down-regulated (as observed in RNAseq data) in both diseases 
and repressed by miR-96 in the shared regulatory network generated using miRconnX. 
To interrogate all genes that change with overexpression of miR-96, we ran gene 
expression arrays on RNA from our miR-96 overexpression studies. GSEA of these 
arrays revealed that genes that go up with overexpression of miR-96 in epithelial cells 
were enriched for genes that also go up in IPF relative to control (Fig. 9). Importantly, 
	  
Fig. 8: Validation of SLC1A1 and SH3BP5 in Fibroblasts and Epithelial Cells. miR-96 was 
overexpressed in fibroblast and epithelial cell lines. Overexpression of miR-96 induced 
decreased expression of SLC1A1 and SH3BP5. 
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this result revealed that overexpression of miR-96 recapitulated some of IPF associated 
increases in gene expression and suggests its potential as a therapeutic target.  
Discussion 
This study represents the most encompassing transcriptomic study of non-
malignant chronic lung disease to date, and our particular study design empowered us to 
define the disease networks that are shared across two lung conditions: COPD subtype 
emphysema and IPF. While these two diseases have distinct clinical, radiographic and 
pathological manifestations, they share a common environmental exposure: cigarette 
smoke. My results suggest the presence of common transcriptional networks associated 
with both diseases which provide insight into the lung’s response to chronic injury.  
	  
Fig. 9: Enrichment of Genes Up with miR-96 Overexpression in IPF vs. 
Control. GSEA was used to test for enrichment of genes up with miR-96 in 
IPF vs. control genes. X-axis represents ranked list. 
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My initial analysis aimed at identifying the convergent molecular network in COPD 
and IPF at the gene-expression level. One of the striking findings from that analysis was 
the relatively large number of genes that were differentially expressed between IPF and 
normal lung, as compared to the number of genes that are differentially expressed 
between emphysema vs. normal lung. These findings may be driven by distinct cellular 
changes that characterize the fibrotic foci that were profiled compared to the more 
heterogeneous cell type composition in emphysema. Despite the cellular differences 
between conditions, I identified a shared molecular network enriched for the up-
regulation of the p53/hypoxia pathway. When the p53 pathway is triggered by hypoxia 
instead of DNA damage, as I suspect happens in lungs with emphysema or IPF, apoptosis 
is not triggered. Specific members of the p53/hypoxia pathway have previously been 
shown to be up-regulated in one of the two diseases, including HIF1A, TP53, MDM2, 
CDKN1A, and BAX in IPF 115,116 and TP53 and BAX in emphysema 117.  Our work, 
however, provides an important advance by profiling both diseases simultaneously and 
characterizing additional components of this pathway that are similarly altered in both 
diseases. The upregulation of certain members of this pathway is of interest because these 
members are also upregulated in cancer, which emphysema and IPF are risk factors for.  
Specifically, HIF1A is transcribed at high levels in many tumors, and high expression is a 
marker of invasiveness and malignancy118.  HIF1A activates p53.  Activated p53 causes 
potent oncogene MDM2 to be transcribed, which then in turn ubiquinates p53119.   Other 
shared p53 pathway members upregulated in both diseases includes SESN2, which is 
directly activated by p53 and is a critical part of the antioxidant response120.  Further 
	  	  
28 
functional studies beyond the scope of this work are needed to pin down the exact role 
that the p53 pathway is playing, as current analysis provides a view only of transcript 
levels, not phosphorylation, ubiquination, or any number of other post-translational 
regulatory mechanisms.   
A second approach explored the shared molecular network between IPF and COPD 
by synergizing the mRNA-seq and microRNA array data generated on the same lung 
tissue samples. The resulting network revealed that both diseases share common 
transcriptional regulatory motifs, with several microRNAs in common between 
regulatory networks. Of particular interest is MIR-96, which is up-regulated in both 
diseases and is suggested to regulate a number of genes differentially expressed in both 
IPF and COPD including SCL1A1, SH3BP5, LDB2, and ARHGAP24. SCL1A1 is a 
glutamate transporter, which is down-regulated under hypoxic conditions121,122. SH3BP5 
inhibits BTK123, which is a binding partner of Hypoxia Induced Mitogenic Factor 
(HIMF)124. LDB2 binds to LIM domain binding proteins125, which inhibit HIF1A126. 
Importantly, we were able to demonstrate that overexpression of MIR-96 in both lung 
epithelial cells and fibroblasts in vitro recapitulates components of the shared COPD-IPF 
gene-expression network, providing further evidence that MIR-96 may be an important 
regulator of the shared disease gene-expression network.  
While the unique study design and comprehensive transcriptional profiling provided 
an unprecedented resolution of the lung transcriptome in health and disease, there are a 
number of important limitations to this analysis. We profiled whole lung tissue and thus 
some of the differential gene-expression identified between emphysema or IPF as 
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compared to control may simply reflect differing proportions of lung cell types. To 
address this concern, we pursued immunohistochemistry IHC to validate the cell type 
responsible for expression of a select number of genes. Despite the difference in cell 
types, the convergence of overall differential expression signals suggests the observed 
changes are due to disease biology. Given the cross-sectional nature of our study, we 
cannot readily distinguish gene expression changes that are causal versus consequential 
of the disease process. The integrative mRNA-miRNA network and the subsequent 
functional validation studies in vitro provide some evidence for a causal relationship 
between regulatory miRNA and the disease-associated gene expression network but do 
not prove direct first-degree regulation. Additionally, some of the control lungs were 
taken from smokers with lung cancer, suggesting that a portion of the differential 
expression could be driven by the influence of the tumor on the lung as a whole. To limit 
this potential effect, our collaborators used SNP arrays from the lung and blood to filter 
out samples with cytogenetic abnormalities.  
In summary, the first aim of my thesis has exhibited the ability of next generation 
sequencing to provide unprecedented resolution of the lung in healthy and disease states. 
Importantly, by profiling distinct lung diseases in parallel within the same study, we 
uncovered molecular networks that are shared among smokers with IPF and emphysema. 
Our study also shows the necessity of integrating diverse genomic data from the same 
specimen in order to discover disease associated regulatory networks. With additional 
functional validation studies, these networks may not only provide insight into disease 
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pathogenesis, but could eventually lead to novel diagnostic biomarkers and therapeutic 
targets for chronic lung disease. 
 
Materials and Methods 
Sample Collection 
As part of the LTRC we collected lung tissue samples. We evaluated the initial 89 
samples for potential field of cancerization effects, as some samples were collected from 
areas adjacent to lung cancer tumors. Two control samples contained between 12% and 
25% abnormal cells by allele balance via the Illumina Infinium genotyping array and 
were thus removed from further analysis. 
Patient Demographics 
Remaining were n=19 COPD subjects with predominant Emphysema phenotype, 
n=17 COPD subjects without predominant emphysema phenotype (COPD airways 
disease), n=19 IPF subjects, n=13 COPD subjects with intermediate emphysema 
phenotype, and n=20 histologically normal tissue samples. 75 of the remaining 87 
samples were selected by pathologists as displaying the most distinct phenotypes and 
were used for differential large and small RNA analysis (Supplemental Table 1). The 
COPD categories were defined based on the percent emphysema: samples with <10% 
Emphysema and >30% Emphysema were used to define the COPD airway and 
Emphysema phenotypes respectively. The ILD samples were subset down to those with 




We extracted total RNA from all lung samples using the QIAcube system (QIAGEN 
Inc., Valencia, CA) with the miRNeasy kit. RNA quality was determined using a 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara CA) with a RNA Integrity Number 
(RIN) > 7.0 as the criterion for acceptable quality. 
Large RNA-seq 
Library preparation and mRNA sequencing was performed on each of the 89 
LGRC samples. The mRNA was isolated using poly(A) selection, fragmented, and 
randomly primed for reverse transcription followed by second-strand synthesis to create 
double-stranded cDNA fragments. Ends were repaired, ligated to Illumina Paired-End 
sequencing adapters, and fragments of 300 bp were obtained through gel-based size 
selection. These fragments were PCR amplified, purified, and then subjected to cluster 
generation using Illumina Paired-End Cluster Generation Kit v4. Each sample was 
sequenced on 1 lane of an Illumina Genome Analyzer IIX to generate 30-40 million 75 nt 
paired-end reads having an average inner distance between mate pairs of 50 bp. 
Initial data processing was done using Illumina GA pipeline version 1.3. The 
quality of each sample sequenced was assessed by examining several Illumina metrics 
such as the percent of clusters passing the filter, the density of the cluster passing the 
filter, and the number of sequencing cycles with a median phred quality score (log of 
base calling error probability) less than 30. In addition, we examined the distribution of 
the quality scores as a function of position, the nucleotide composition as a function of 
position, and histograms of the inner distance between paired end reads mapped to the 
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genome using our own custom perl scripts as well as the FastQC java program by Simon 
Andrews at Babraham Bioinformatics 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
After samples were evaluated for quality, we aligned the samples to the human 
genome using Tophat version 1.2127. Tophat is a gapped aligner specifically optimized for 
RNA-seq data which identifies the reads that align to the genome as well as reads that 
span known and novel exon-exon splice junctions. We aligned the reads as pair ends. We 
allowed up to 2 mismatches per 25 nt segment and allowed the default number of multi-
reads. Tophat was run by specifying Illumina GA pipeline version 1.3 or greater, 
unstranded library, a mate inner distance of 50, and a mate standard deviation of 100. 
After alignment, samples were again assessed for quality by examining the number of 
reads that aligned uniquely and the number of reads that aligned with varying number of 
mismatches. The first and second principle components were also assessed as part of 
post-alignment quality control. No outliers were found based on these analyses. 
The results of the gapped alignment were used to quantify the number of reads 
mapping to each gene. We generated gene level expression estimates for each of the 87 
samples using Cufflinks Version1.1.0102. The gene annotation for genes containing 
multiple transcripts was created by including common and unique regions of each 
transcript. Cufflinks was run to only quantify known transcripts through the use of a 
modified Ensembl59 GTF. Furthermore Cufflinks was run such that it performed upper 
quartile normalization, multi-read correction, and nucleotide bias correction. 
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First, we log2 transformed FPKM gene expression data from Cufflinks. Using 
their “on” or “off” status and coefficient of variance, we filtered genes. To determine a 
given gene’s status we used a modified version of the mixture model in the SCAN.UPC 
Bioconductor package128. For a gene to be included in differential expression analysis, it 
had to be classified as “on” in at least 25% of samples out of the two phenotypic groups 
being compared, but regardless of phenotype. Next, the bottom 20% of genes were 
filtered out based on their coefficient of variation. 
mRNA and miRNA Array Processing 
RNA from each subject was reverse transcribed, labeled with cyanine-5, and hybridized 
to Agilent V2 Human Whole Genome microarrays. The samples were randomized both 
by disease state and order in which the samples were hybridized to minimize batch 
effects. Immediately after hybridization and subsequent washing with Agilent Gene 
Expression Wash Buffer, the microarrays were scanned using the Agilent DNA 
Microarray Scanner. The resultant data was globally normalized using cyclic loess by in-
house software built in the R programming environment. Differential gene expression 
was measured using BRB ArrayTools developed by Dr. Richard Simon and BRB-
ArrayTools Development Team. RNA prepared as described above was also hybridized 
to the Agilent Human miRNA Microarray (V3). Samples were again randomized to avoid 
batch effects. Arrays were washed with Agilent miRNA Expression Wash Buffer and 
scanned using the Agilent DNA microarray Scanner. The data as then quantile 
normalized using GeneSpring. 
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Modeling Disease Associated Changes in Gene Expression 
I identified differentially expressed genes with the limma R package. For 
Emphysema, we included only samples with greater than 30% emphysema. From the 
Interstitial Lung Disease population, we included only samples with pure Idiopathic 
Pulmonary Fibrosis. I included only genes annotated as “known” in Ensembl. Overall, we 
chose samples such that age, pack years, smoking status, and gender were not 
confounded with disease status. We acquired tissues from the Lung Tissue Research 
Consortium (LTRC). As previously described, we performed Immunohistochemistry 
employing mouse monoclonal antibodies directed against MDM2 (Millipore, Temecula, 
CA), HIF1A (Stressgen, Victoria, BC, Canada), and NFKBIB (ABD Serotec, Raleigh, 
NC), and a rabbit polyclonal antibody directed against PDGFA (Santa Cruz 
Biotechnology, Santa Cruz, CA). We took all brightfield images with an Olympus DP25 
camera on an Olympus CH2 microscope129. We integrated miRNA array and mRNA-Seq 
data with MirConnX114. This tool combines a prior, static network created from miRNA 
binding predictions and literature validation with user submitted data to create a 
transcriptomic gene regulatory network. For each condition-control comparison, we 
filtered to only differentially expressed mRNAs. We inspected resulting regulatory 
networks for potential regulatory hubs (miRNAs with a high number of connected 
mRNAs).  
P53 Pathway Validation with Gene Expression Arrays 
Using a t-test in limma (same as for RNAseq analysis) I identified disease 
associated changes in gene expression. Genes in Ensembl without Agilent probe 
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mappings were excluded from analyses. Platforms were compared by evaluating the 
overlap between genes identified as differentially expressed. Correlation between t-
statistics on the two platforms was found using a Pearson correlation. 
Overexpression of miR-96 
NHLF p.6 (Lonza) were plated at 70% confluence (150,000 cells per well in 6-
well plate) in FGM™-2 BulletKit™ medium (Lonza). After 6 hours media was replaced 
by Opti-MEM (Invitrogen) over night. 20nM of miR-96 and negative control (scramble) 
(Applied Bio Systems) were transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. Media was replaced back to growth media 
after 6 hours. RNA was isolated 24h post-transfection. 
Immortalized human bronchial epithelial cells (Beas-2B) were cultured in BEGM 
growth medium (Lonza) and plated at a 50% confluence in 6-well plates 24h before 
transfection. 100pmoles of pre-miR-96 or a Cy-3-labeled scrambled control (Ambion) 
were transfected into the cells using Lipofectamine RNAiMAX (Invitrogen) as per 
manufacturer’s protocol. Cells were harvested at 48 hours post-transfection and total 
RNA was isolated using the miRNeasy mini kit (Qiagen).  
To measure the expression of SLC1A and SH3BP5 in both of the above cell lines, 
total RNA was reverse transcribed using random hexamers (Applied Biosystems) and 
Superscript™II reverse transcriptase (Invitrogen). 20ng of starting cDNA product was 
added to SYBR® Green PCR master mix (Applied Biosystems). The primer sequences 
are as follow: SLC1A forward (5’- TAG GTA TTG TGC TGG TGG TGA G -3), SLC1A 
reverse (5’-TGA GAT CTA ACATGG CAT CCA C-3’), SH3BP5 forward (5’-CGA 
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GCA ACT GAA AAA GAC TGT G-3’) and SH3BP5 reverse (5’-TTC TTC AGG GCC 
ATC TTG TAC T-3’). Forty cycles of amplification were used and data acquisition was 
carried out with the StepOne Real Time PCR System (Applied Biosystems). The data 
was analyzed using the comparative CT method 130. 
In order to perform mRNA microarray profiling, 50ng of total RNA from the 
BEAS2B cell line was extracted and used as a template for double stranded cDNA 
synthesis. The cDNA was used as a template to generate Cy3 labeled cRNA (using the 
low input kit) to be used after for hybridization. After purification and fragmentation of 
the samples was performed and were hybridized to Agilent SurePrint G3 Human Gene 
Expression 8x60K v2 Microarray at 65°C for 17h. Each array, after hybridization, was 
sequentially washed and scanned by Agilent Microarray Scanner. Images were processed 
using Agilent’s Feature Extraction software version 10.7.3.1. 
Functional Enrichment of COPD, IPF, and COPD/IPF Gene Expression 
DAVID was used to assess overrepresented functional categories or biological 
pathways in a given list of genes. In addition, GSEA was used to select enriched 
pathways in a ranked list (t-statistic) of COPD vs. control and IPF vs. control. Similarity 
of enrichment was assessed by reviewing concordance of the Normalized Enrichment 





Never Smoker Lung Adenocarcinoma Exhibits Unique Transcriptomic 
Perturbations 
Background and Introduction  
 Lung cancer is the leading cause of cancer-related death worldwide, claiming over 1 
million lives annually131. While	  lung	  adenocarcinoma	  is	  predominantly	  considered	  a	  “smoker’s	  disease”,	  approximately	  25%	  of	  these	  cancers	  arise	  in	  those	  who	  have	  never	  smoked,	  and	  it	  is	  the	  predominant	  cause	  of	  cancer	  related	  deaths	  among	  never	  smokers31. The number of lung cancer deaths among never smokers has increased 
annually and is currently estimated to be the seventh leading cause of cancer mortality132.  
 Recent studies suggest that current or former (ever) smokers and never smokers who 
develop lung cancer harbor distinct profiles of somatic mutations and elicit disparate 
responses to targeted therapy63,64. EGFR oncogene mutations are present in 45% of never 
smoker lung cancers, but only 7% of ever smoker lung cancers57, and can be exploited for 
targeted therapy with EGFR-TK (Tyrosine Kinase) inhibitors. Other molecular 
abnormalities, including p53 mutations, KRAS mutations, chromosomal aberrations, 
gene expression, and methylation profiles, all also vary between the lung tumors of never 
smokers and ever smokers84,131,133. This type of translational research has underscored the 
therapeutic value of identifying distinct molecular drivers and precipitates the need for a 
thorough comparison of the molecular differences between lung cancer cases in ever and 
never smokers.     
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 Based on this evidence, we hypothesize that lung adenocarcinoma arises through 
distinct molecular processes in never smokers compared to ever smokers, and that these 
separate mechanisms of lung carcinogenesis necessitate different therapeutic approaches. 
By leveraging emergent transcriptomic sequencing technologies we are able to profile 
messenger RNAs as well as more exotic members of the transcriptomic zoo, such as 
noncoding RNA. In this study we sequence large and small RNA from the same patients. 
Thus, we are able to identify disease-associated changes in mRNA expression, miRNA 
expression, and the miRNA-mRNA regulatory network (Fig. 10, study overview). 
Network analysis in this study revealed a key miRNA-mRNA pair that appears to 
regulate tumorigenic gene expression and oncogenic phenotypes uniquely in never 
smoker tumors. Moreover, this transcriptomic analysis of never smoker lung cancer 
represents a critical first step in being able to extending our previously published 
bronchoscopy based lung cancer biomarker134 from ever smokers into never smokers.   
	    
	  
Fig. 10: Overview of Study. Purple represents current smokers, green represents former 
smokers, light grey represents never smokers.  Grey with a red box around it represents sought 




Characteristics of Study Population and Samples Collected 
Patients undergoing resection of lung adenocarcinoma, bronchioloalveolar 
carcinoma, or squamous cell carcinoma were recruited into this study. Samples originated 
at the Mayo clinic, and were sent to Lovelace Respiratory Research Institute where tumor 
purity was checked and RNA was isolated. The patient population contains a mixture of 
male and female patients, including current, former, secondhand, and never smokers 
(Table 4). All patients with squamous cell carcinoma are current or former smokers, all 
patients with bronchioloalveolar carcinoma are never smokers, and the patients with 
adenocarcinoma are a mix of all smoking statuses. For this analysis, I included only lung 
adenocarcinoma patients to compare the effect of smoking status.  
  
Tumor Gene/miRNA Expression Profiles Associated Uniquely with Never Smoker Tumors 	   In order to identify changes in gene expression associated with the never smoker 
tumor, I utilized linear modeling. Strikingly, a linear mixed effects model with an 
	  
Table 4: Demographics of Original RNAseq cohort. 
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interaction term followed by a post-hoc paired t-test pinpointed 120 large RNAs and 15 
miRNAs uniquely changed in the never smoker tumor (Fig. 11, pval < 0.01 for lme and 
pval < 0.05 for paired t-test). Out of the 120 large RNAs, 49% are protein coding, 17% 
are lncRNAs and 34% are other ncRNA. Many of the noncoding RNA can easily be 
spotted in the heatmap by their distinctive “on” or “off” expression pattern. Some of the 
expression level alterations in protein coding genes have been previously reported to be 
important in other cancers, such as MDM2 being up and RBP1 being down	  
 in the never smoker tumor (Fig. 12A, 12B). The large RNA signature also revealed 
changes in potential key regulators such as the downregulation of lung development 
transcription factor FOXP2135 (Fig 12D).  
  
	  
Fig. 11: Never Smoker Tumor Specific Changes in Large and Small RNA Expression.  Expression pattern of 
RNA differentially expressed in the tumor vs. adjacent normal of never smokers but not the tumor vs. 
adjacent normal of ever smokers A. 120 genes are differentially expressed uniquely in the never smoker 





In order to confirm our findings, we compared our 120 gene signature for never 
smoker tumor to RNAseq data from TCGA and microarray gene expression data from 
Landi et al. 200884 (Table 5). Both of these computational datasets contain paired tumor 
and adjacent normal samples from current, former, or never smokers with lung 
adenocarcinoma. The never smoker tumor specific gene expression signature was split 
into two gene sets based on direction of change. The activity of the two gene sets was 
scored per sample across expression data from the independent sequencing and array 
	  
Fig. 12. Never Smoker Tumor Specific Gene Expression Changes.  
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datasets using GSVA136. Running the same linear mixed effects model with an interaction 
term followed by a post-hoc t-test (only including genes significant in the first step) on 
the generated GSVA gene set scores yielded statistically significant results, showing that 
our signature is present in independently generated computational data. Specifically, 
when the set of genes down in the never smoker tumor were transformed into a single 
GSVA score per sample using data from Landi et al.84, the same linear model approach 
and p-value cutoffs as used in the initial analysis yielded statistically significant results.  
(lme p-value = 0.01, post-hoc t-test p-value at 0.001 (Fig. 13A). In support of this finding 
in the Landi data, the set of genes up in the never smoker tumor, when tested in per 
sample scored TCGA data, had a p-value of 0.045 in the interaction model and 0.03 in 
the never smoker tumor vs. adjacent normal model (Fig. 13B). These results show that 
the never smoker tumor specific gene expression signature validated in independently 
collected and profiled samples. 
	  
Table 5: Demographics of Independent Gene Expression Array and RNAseq 




Functional Enrichment of Never Smoker Specific Tumor Expression 
Genes up in the never smoker tumor are enriched for pathways such as GO 
Epithelial Cell Differentiation, GO negative regulation of immune response, activation of 
Jun Kinase activity, and Biocarta Multidrug Resistant Proteins (p-value < 0.03). 
Moreover, several of the signature’s genes upregulated in never smoker tumors have been 
implicated in other cancers. For instance, MDM2137 and CABIN1138 are known to inhibit 
p53 transcriptional activity and MDM2 has been suggested as a target for chemotherapy 
in ovarian cancer and others119,139,140.  Additionally, high expression of four never smoker 
tumor specific genes causes breast cancer oncogenic phenotypes: ABCC3 (Human 
Multidrug Resistance Protein141) confers resistance to chemotherapy142, PLXNB1 
	  
Fig. 13: Never Smoker Tumor Specific Genes Show Enrichment in Independent Gene Expression 
Array and RNAseq Dataset via GSVA. A) A per sample estimate was calculated for the genes 
which are down in the never smoker tumor but not the ever smoker tumor as compared to 
adjacent normal in array data from Landi et al., showing statistically significant enrichment. B) 
A per sample estimate was calculated for the genes which are up specifically in the never smoker 
tumor in RNAseq from TCGA, showing statistically significant enrichment.  
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promotes metastasis, FAM83B drives epithelial cell transformation143, and GPR110 
increases anchorage independent growth144 leading to metastasis. Lastly, PLXNB1145 and 
GDF15146 have also been implicated in ovarian cancer.  
  
Never Smoker Tumor Specific mRNA-miRNA Regulatory Network 
To gain insight into the regulation of never smoker lung cancer, we used mirconnX to 
build a regulatory network two different ways using large RNAseq and miRNAseq data. 
First, a directed weighted network was constructed using never smoker expression of all 
protein coding genes and never smoker tumor specific miRNA. The network contains 7 
miRNAs perturbing 591 protein coding genes, for a total of 592 interactions (Fig. 14A).  
	  
Fig. 14: Two Perspectives on the Never Smoker Tumor Specific Regulatory Network.  Mir-424 
is circled in yellow.  A) All protein coding genes and 15 never smoker tumor specific miRNA 
were used to create this network B) Only 59 never smoker tumor specific mRNAs and all 
miRNAs were used to create this network. 
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A second network was built including only 59 never smoker tumor specific protein 
coding genes (subset of 120 genes which have miRNA predictions in mirconnX) and all 
miRNA.  This network contains 33 miRNAs perturbing 12 protein coding genes, for a 
total of 52 regulatory connections (Fig. 14B).  Mir-424 is centrally connected in both of 
these networks, has previously been implicated as a driver of angiogenesis in other 
cancers147–149, and is directly connected to key pulmonary developmental transcription 
factor of interest FOXP2. Functional enrichment of mRNAs connected to mir-424 (Fig. 
14A) reveals KEGG Melanoma, pancreatic cancer, Biocarta RECK pathway, GO 
anatomical structure development all at pval < 0.01.   
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PCR Validation of mir-424 and its Target FOXP2 Original Samples and Independent 
Samples 
Additional independent samples including tumor, adjacent normal, and small airways 
near tumor were collected from MD Anderson (5 current, 14 former, 14 never smokers, 
Table 6). Potential key regulatory hub, mir-424 and its transcription target FOXP2 were 
validated by qRT-PCR in these independent tumor and adjacent normal samples and in 
the original sample set, analyzed together with pval < 0.05 (Fig. 15) when compared 
between never and ever smokers. qPCR showed that mir-424 is expressed at a higher 
level in the small airways near the adenocarcinoma tumor in never smokers than ever 
smokers (Fig. 16). Together, computational and experimental testing demonstrate that our 
	  
Fig. 15: qPCR Validation of miR-424 and its Target FOXP2. * = pval < 0.05.  
	  
Table 6: Demographics of Independent Cohort from MD Anderson. 
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signature validates both as a whole computationally with GSEA and for specific genes 
via qPCR in independent groups of samples. This suggest that our signature is robust and 
will replicate in any future studies with additional independent samples collected, 
whether the testing is done with RNAseq, microarrays, or qPCR. 
Identification of Never Smoker Adenocarcinoma Therapeutics via the Connectivity Map 
Although developing drugs against a certain target is a feasible approach for 
developing new therapeutics for lung cancer, identifying FDA approved compounds that 
could be repurposed may have a shorter path to the clinic. The Connectivity map (Cmap) 
helps investigators identify already existing FDA approved bioactive compounds which 
may reverse a molecular phenotype of interest. Specifically, the Cmap is a large publicly 
available compendium of microarray data reflecting gene-expression responses to drug 
therapy. I leveraged the Cmap to identify compounds that reverse the 120 gene never 
smoker tumor specific expression pattern. One of the most significant hits is a drug called 
	  
Fig. 16: miR-424 is Upregulated in the Small Airways 
Near the Tumor in Never Smokers in an Independent 
Cohort. Expression of mir-424 was queried in the small 
airways near the tumor of ever and never smokers with 
lung adenocarcinoma. X-axis is relative expression. 
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Altretamine (p=0.002). This chemotherapeutic is currently in use in the clinic in ovarian 
cancer150. Interestingly, never smoker lung cancer is much more common in females31, 
hinting that gender may play a role in never smoker lung cancer development and could 
influence efficacy of chemotherapeutics. Althgouth Altretamine works as an alkylating 
agent, through a mechanism similar to mustard gas151, its exact mechanism of action 
remains to be characterized thoroughly.   
Discussion 
 Our study represents the most comprehensive profiling of the regulation of never 
smoker lung cancer to date. Here, we leverage high-throughput high-coverage large and 
small RNA sequencing of tumor versus paired adjacent noncancerous lung tissues 
resected from adenocarcinoma patients with varied smoking histories. Building on 
previous work showing clinical and genomic differences between ever and never smoker 
lung adenocarcinoma, we have revealed unique changes in the transcriptomic landscape 
of never smoker lung adenocarcinoma compared to ever smoker lung adenocarcinoma.  
 Differential expression analysis of large and small RNA from clinical specimens as 
stratified by smoking status has enabled us to gain unprecedented insight into the 
regulatory networks underpinning lung carcinogenesis. The large RNA changes 
discovered in our dataset were significantly related to results generated in two 
independent gene expression profiling experiments from different laboratories. 
Interestingly, famous cancer genes such as RBP1 and MDM2 were uncovered by this 
analysis, suggesting that the set of genes is likely related to oncogenesis in never 
smokers. In a literature review of all upregulated never smoker tumor specific genes, it 
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can be observed that many of these genes have already been implicated in ovarian and 
breast cancer. Although this observation is casual rather than statistical, it is interesting to 
note that never smoker lung cancer occurs at much higher frequency in women, 
suggesting that further investigation is needed to determine if there are any shared 
mechanisms. Adding to this observation, the connectivity map suggested ovarian cancer 
drug Altretamine as a drug to reverse the never smoker tumor specific signature.  
  Although finding a protein coding drug target can be a desirable outcome, many have 
suggested that miRNAs may be better drug targets as they regulate entire pathways152,153. 
To explore this possibility, network analysis was performed by integrating select mRNA 
and miRNA expression data with a network of prior putative targets. This analysis 
uncovered a mRNA-miRNA regulatory network which regulates gene expression 
changes unique to the never smoker tumor. Together the large RNA analysis and network 
analysis support the hypothesis that never smoker lung adenocarcinoma is a disparate 
disease from ever smoker lung cancers and triggers the need to identify therapeutic 
targets specific for never smokers. 
 To address this clinical need, miR-424 is identified as a key hub in the never 
smoker specific lung adenocarcinoma regulatory network because of its high degree of 
regulatory connections in the network. miR-424 has mRNA targets that are important in 
many pathways, specifically in those pathways that would be affected by cancer. This 
miRNA has been reported to play an oncogenic role in colorectal and pancreatic cancers, 
and is highly connected in our never smoker tumor regulatory network. Our network 
predicted that mir-424 suppressed FOXP2, a transcription factor important in lung 
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development. Unique never smoker tumor perturbation of mir-424 and FOXP2 was 
confirmed using qRT-PCR in an independent set of samples.  Preliminary data suggests 
that this pattern of miR-424 expression extends into the small airways of an independent 
cohort of never smokers with lung adenocarcinoma, raising the possibility of a field of 
injury specific to never smokers.  At this time, further functional characterization of mir-
424 and FOXP2 is needed to understand their potential as therapeutic targets and their 
roles in the airway epithelium. 
 The oncogenic, never smoker specific molecular derangements detailed in this study 
will ultimately contribute to the development and clinical deployment of new therapies 
for lung adenocarcinoma in never smokers. 
Materials and Methods 
Patient Demographics 
Current, former, and never smokers who had no history of other exposures 
underwent surgery as part of their treatment, at which point samples were collected. At 
the time of collection, current smokers had a higher pack year burden than former 
smokers (p<0.05). The three groups were well balanced for age with a mean of 55 years 
for each group. There was an insignificant but higher ratio of females in the never smoker 
group. RIN (RNA Integrity Number) differed between all three groups (p<0.05), but was 
not found to be associated with results and thus not confounding. 
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Sample Collection and Processing 
Through a collaboration with Lovelace Respiratory Research Institute, (LRRI), 
samples were collected from patients undergoing tumor resection at the Mayo clinic. 
Collected samples were sent to LRRI, where RNA was isolated and then shipped to 
Boston University.  
Library preparation was done using Illumina’s TruSeq (RNAseq) sample preparation 
kit starting with 200-500 ng of total RNA from each sample. The large RNA was isolated 
using poly-A selection and fragmented to get a range of fragment lengths centered around 
200 nucleotides. Fragments were randomly primed for reverse transcription followed by 
first and second-strand synthesis to create double-stranded cDNA fragments. cDNA ends 
were repaired, ligated to a unique barcoded index paired end adapter. These fragments 
were then PCR amplified, purified, and subjected to cluster generation on a cBot machine 
using Illumina TruSeq Paired-End Cluster Generation Kits. Next, the samples were 
sequenced four per lane on a HiSeq machine. Sequencing generated approximately 40 
million 99 nucleotide paired end reads with an average inner distance of -25 nucleotides.  
 The small RNA fraction (fewer than 200 nucleotides) was isolated and then 200ng 
was processed using the Illumina TruSeq Small RNA Sample Prep Kit. Samples were 
multiplexed and sequenced on the Illumina HiSeq 2000 generating 35-bp reads. Up to 10 




Processing of Large RNA and miRNAseq Data 
mRNA and miRNA fastq files were initially filtered for quality using fastqc. mRNA 
reads were aligned to hg19 using Tophat101, and quantified to Ensembl using Cufflinks102. 
After adapter trimming with the fastx toolkit, miRNA reads were aligned with Bowtie101, 
counted with bedtools154, and RPM normalized. QC metrics were reviewed, such as 
alignment statistics and PCA. One sample and its pair were excluded for low QC metrics 
and PCA outlier status. The bottom 30% of genes by mean FPKM and the bottom 30% 
by variance were removed from further analysis. miRNAs with an average count below 
20 were removed. These filtering methods were employed to avoid testing genes 
ineligible for linear modeling. An overview of sequencing processing methods can be 
seen in Fig. 17. 
	  
Fig. 17: Processing of RNAseq Data. 
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Linear Modeling to Find Unique Tumor Genes and miRNAs by Smoking Status 
 Model 1 (RNA = tissue + smoking, random=~1|patient) accounts for tissue, smoking 
status, and patient. ‘Tissue’ is a fixed effect controlling for the histology and site of the 
sample (tumor or adjacent-normal), and ‘Smoking’ is a fixed effect controlling for the 
smoking status of the patient (ever or never). ‘Patient’ is a random effect controlling for 
patient specific effects. Model 2 (RNA = tissue + smoking + tissue:smoking, 
random=~1|patient) contains an additional interaction effect between histological status 
of the tissue sample and smoking status of the patient. The two models were compared by 
a likelihood ratio test and those genes with a p value of less than 0.01 were determined to 
	  




be associated with the interaction between tissue type and smoking status. To determine 
the direction of change of these genes, a post-hoc paired t-test was done separately in 
ever and never smokers between tumor and adjacent normal tissue, and identified never 
smoker tumor specific changes in gene expression. To be considered a never smoker 
tumor specific gene, the never smoker t-test had to have a p-value of less than 0.05 and 
the ever smoker t-test had to have a p-value of greater than 0.25. This would indicate that 
the gene was significantly differentially expressed between tumor and adjacent normal in 
never smokers but not significantly differentially expressed in ever smokers.  An 
overview of this approach can be seen in Fig. 18.  
 The resulting signature was validated using GSVA.  Microarray expression data was 
downloaded from GEO, and RPM normalized RNAseq data was downloaded from 
TCGA portal.  Patients with the smoking status “reformed smokers quit >= 15 years” 
were excluded from TCGA dataset.  The never smoker tumor specific gene expression 
signature was split into groups by direction.  These two gene sets were projected into 
Landi et al. and TCGA expression data.  The same linear models as above were then run 
on these independent datasets and tested for significance.     
Pathway Identification 
EnrichR was used to determine pathway enrichment. First, the signature was split 
by up-in-the-never-smoker-tumor or down-in-the-never-smoker-tumor. These two gene 
lists were uploaded separately to enrichR. Scores for each gene were not included.  
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mRNA-miRNA Construction with miRconnX 
 MirconnX was used to build an integrated anticorrelation prior information network, 
leveraging expression values from large RNA and miRNAseq as well as miRNA target 
prediction information. The network was constructed by submitting the expression data 
for only the samples which had both mRNA and miRNAseq data. Gene expression for all 
protein coding genes that passed the filter and the 15 significant miRNA were submitted 
to mirconnX, and then a second network was created by submitting only significant 
protein coding genes and all miRNA. 
qRT-pcr Validation of mir-424 
 Under IRB approval, tumor, adjacent normal, and small airway brushings were 
obtained from ever and never smokers undergoing tumor resection surgery at MD 
Anderson.  RNA was isolated and shipped to Boston University.  MiR-424 expression 
was measured by qRT-PCR in 32 ever smoker and 20 never smoker paired lung 
adenocarcinoma and adjacent normal tissue. Samples were analyzed with qRT-PCR 
using Taqman assays and RNU44 as a control. FOXP2 was measured in the same 
samples with qRT-PCR using Qiagen RT2 Primer Assay and UBC as a control. Fold 
change for both miR-424 and FOXP2 was measured by dividing the relative expression 
of the tumor with the relative expression of the adjacent normal in each matching pair.  
Additionally, MiR-424 expression was measured by qRT-PCR in 19 ever smoker and 14 
never smoker small airway brushing samples (collected near the tumor). Samples were 




Conclusions and Future Directions 
Impact of Shared Emphysema-IPF Gene Expression and Regulatory Network 
Emphysema and IPF are both progressive diseases with a dearth of therapeutic 
options to address the underlying disease mechanism. Funding has been historically low 
for these diseases, especially when contrasted with incidence and mortality rate. 
Clinicians lack not only effective treatment options, but also adequate tools to determine 
the rate at which patients will decline. This is ultimately because of a lack of 
understanding of molecular mechanisms of the diseases. 
Although other publications have speculated about the existence of shared 
pathways, this study, by profiling COPD and IPF together, conclusively demonstrated 
that these two diseases have common pathways.  To an outside observer this may be 
surprising as COPD and IPF have different clinical presentations.  COPD appears to be 
more of a disease of wasting whereas IPF is characterized by deleterious fibrosis.  
However, both diseases have an overlapping risk associated with them: cigarette 
smoking.  Based on this, one possible hypothesis is that gene expression changes in 
common are more likely to be causative than reactionary.   
The major impact of this discovery of shared gene expression on the field is the 
presentation of a pathway and a miRNA as potential therapeutic targets. The hypoxia 
component of the p53 pathway was found to be upregulated in both emphysema and IPF 
lung tissue. Fortuitously, this is a pathway that is already well characterized due to its 
prominent role in tumorigenesis and oncogenesis in malignant disease.  Drugs that can 
perturb members of this pathway already exist, and a subset is FDA approved. Hopefully 
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this means that existing drugs can be pivoted rather than having to develop drugs de 
novo. Interestingly, a patient diagnosed with COPD is more likely to develop lung 
cancer, and vise-versa.  Since COPD is a risk factor for lung cancer and the p53 pathway 
has been implicated in both diseases, one can infer that targeting this pathway could be 
used in a chemoprevention and/or COPD-prevention setting. 
Secondly, although miRNA targeting is a much newer field, several clinical trials 
demonstrate feasibility in a human disease setting155. MiR-96 shows promise for both 
diseases, but especially for IPF.  By miRNA arrays, miR-96 is observed as upregulated in 
IPF. When miR-96 is overexpressed in cell lines, gene expression is perturbed in a way 
that resembles IPF gene expression. Thus, targeting miR-96 for destruction may help to 
reverse the IPF phenotype. Further studies are needed to determine if miR-96 could also 
be a suitable target for emphysema 
Forward progress in the COPD and IPF research space has also been limited by 
disease heterogeneity.  Specifically, part of what makes emphysema difficult to treat is 
variability of severity within a patient and/or between patients. This idea of heterogeneity 
is supported by the current study, which shows that even between highly differentially 
expressed genes within emphysema vs. control lungs, there are some minor gene 
expression differences between at least two clusters of emphysema lungs (Fig. 3).  
Analysis of associated clinical variables shows that one group may trend toward being 
“less healthy” than the other by select variables but this trend is not significant. 
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Impact of Never Smoker Tumor Specific Gene Expression Signature 
Although lung cancer has for a long time been and is currently the leading cause 
of cancer mortality in the United States, funding in this area has been chronically limited. 
Treatment options as well as a fundamental understanding of the molecular progression 
of this disease are limited to date. Moreover, some genomic evidence exists to suggest 
that there may be major molecular differences between ever and never smokers with lung 
cancer. Despite the potential for these differences, ever and never smokers currently 
receive similar clinical treatment. Results from this thesis add to the hypothesis that never 
smokers with lung adenocarcinoma could be considered as a distinct disease group 
instead of being included with ever smokers. First, this work uncovered unique changes 
in gene expression in the never smoker tumor. These transcriptomic modifications 
represent not only differences in gene expression, but also changes in pathway usage that 
may be driving the development of the tumor. Moreover, there were unique changes in 
miRNA expression in the never smoker tumor. This is particularly relevant in terms of 
target discovery, because miRNA have the potential to regulate entire pathways. Using 
directed integrative networking techniques, my analysis uncovered the potential never 
smoker tumor miRNA-mRNA regulatory network. While many arms of this network 
could possibly be targeted for chemotherapy or chemoprevention, we initially focused on 
miR-424 because it has been implicated in many other cancers. Initial qPCR validation 
confirmed that miR-424 and its predicted target FOXP2 are perturbed in an independent 
sample set, setting the stage for further validation of the mir-424-FOXP2 regulatory link 
as a potentially drugable interaction. Additionally, qPCR characterization of miR-424 
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expression unveiled higher expression in the small airways near the adenocarcinoma 
tumor in never smoker as compared to ever smokers.  Although preliminary, oncomiR 
expression in the small airways near the tumor implies that never smokers with lung 
cancer may have a field of injury like their ever smoking counterparts. If this hypothesis 
is true, airway gene expression could hold the potential to diagnose lung cancer in this 
cohort.  While additional functional genomic studies are needed to further characterize 
miR-424 and its interaction with FOXP2, this regulatory event could be part of the next 
wave of chemotherapeutics or diagnostics for never smoker lung cancer.   
In addition, chemotherapeutic options in the never smoker lung cancer space are 
still quite limited. The process of moving from an identified target to a clinically useful 
drug is very long and costly. A potentially more rapid approach is to pinpoint already 
FDA approved bioactive drugs and reposition them in the context of never smoker lung 
cancer. Following this logic, I identified Altretamine as a compound which is able to 
reverse the never smoker tumor specific signature. Altretamine is a chemotherapeutic 
already in use for the treatment of ovarian cancer. Interestingly, a casual survey of the 
literature on the never smoker tumor specific signature genes revealed that many have 
been previously implicated in ovarian and breast cancer.  Although further functional 
genomic studies are needed, Altretamine may represent a chemotherapeutic that could be 
repurposed to treat never smokers with lung cancer.  
Limitations 
While this study has provided a thorough investigation of the COPD, IPF, and 
lung cancer transcriptome, there are a number of limitations. Firstly, analysis of changes 
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in gene expression associated with IPF and COPD only included seventy-five samples, a 
subset of all samples sequenced in total. It is well known that IPF and especially COPD 
are highly heterogeneous diseases, and the number of samples represented in this study 
may be insufficient to fully capture this disease diversity within patient groups. Some of 
this heterogeneity can even be observed in the heatmap (Fig. 3) of significant emphysema 
vs control genes. Here, it is clear that there are two subgroups within emphysema. 
Although not statistically significant, it does appear that one group appears to be more 
“ill” than the other, with shorter 6 minute walk distances and worse scores on 
questionnaires.  By analyzing more samples, it would be possible to test if this trend is 
real or a mirage. Moreover, there are major cell type differences between emphysema, 
IPF, and healthy lung tissue. Although the expression of several genes was localized to 
the airway epithelium using IHC, the cell type of expression of the rest of the signature 
remains in question. This problem could be addressed using laser microdissection of 
whole tissue samples to zoom in on airway epithelium or single-cell next generation 
sequencing.  
One other challenge in my study of emphysema in particular is that the variable 
used to measure emphysema severity may not correlate perfectly with severity in the 
exact location sampled and profiled. In this study “percent emphysema” was used, which 
is a representation of the function of the whole lung, not only the section of the tissue 
sampled. In a patient with emphysema, alveolar destruction is variable and thus some 
samples may have more apoptotic cells than others. This could be solved in future studies 
by collecting better annotation on the degree of alveolar destruction severity in the area 
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from where the sample is being collected.  
Lastly, the major limitation preventing the findings of my work in emphysema 
and IPF from having greater impact is the lack of functional validation. While the 
overexpression of miR-96 was profiled with gene expression in cell lines, the effect on 
cell phenotype was never tested.   Moreover, there exist a number of potential drugs to 
target the p53/hypoxia pathway, none of which were tested out in the relevant cell lines in 
this study.  
Like the work in emphysema and IPF, the study of never smoker lung cancer is 
also limited by low sample numbers. Discovery of the never smoker tumor specific genes 
in this study relied on ever smokers as a negative control. In order for a gene to be 
included in the “never smoker tumor specific” category, it had to not be statistically 
significant in a comparison of the tumor and adjacent normal in ever smokers. There are a 
number of reasons why a gene can have an insignificant p-value in a statistical test. My 
choices of statistical model and cutoff assume that a gene is not detected as changing 
because it is truly not different between the ever smoker tumor and adjacent normal. 
However, it is possible that there are not enough patients in the study to detect the 
change, or my choice of statistical test is not robust enough to detect a change. While 
boosting the sample number would partially address this issue, there is no perfect 
solution. The issue of how to prove a lack of connection between a phenotype and an 
effect is an unsolved challenge not only in gene expression studies, but also in other 
fields such as epidemiology.  
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The never smoker tumor signature provides a tantalizing peek into the world of 
large noncoding RNA. Although the original intention of the presented analysis was not 
focused on this breed of RNA, about half of the signal is noncoding. When performing 
RNA sequencing, it is necessary to perform at least one step to avoid sequencing 
ribosomal RNA, which dominates the cellular RNA pool and varies very little between 
cells, conditions, and individuals. In order to avoid sequencing ribosomal RNA, we 
employed a poly-A selection. However, not all large regulatory RNAs are 
polyadenylated. Although the signature contains a large percentage of noncoding RNA, it 
may be providing only a glimpse into critical regulatory circuitry of the never smoker 
tumor.  Furthermore, many long noncoding RNAs are antisense to annotated genes. The 
RNA-sequencing methods used in these studies were not strand-specific so there are 
likely antisense transcripts that could not be identified unless a stranded RNA-seq 
protocol is utilized. The present study also did not probe the relationship between never 
smoker tumor lncRNAs and protein coding genes, which could be used to draw 
hypothesis about the functional role of lncRNAs. 
Next Steps 
One of the overall impacts of this study as a whole is to underscore the 
importance of noncoding RNA. In COPD, IPF, and never smoker lung cancer a miRNA-
mRNA regulatory network was revealed. In order to better characterize the full 
transcriptional potential and regulatory networks of these diseases, whole transcriptome 
sequencing should be employed in the future. Also known as “total RNA” sequencing, 
this methodology enables detection not only of large RNAs such as protein coding genes, 
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but also profiles lncRNAs, pseudogenes, and RNAs which use up miRNAs (sponge 
RNAs)99. In addition, strand specific RNAseq could provide better resolution for the 
alignment of certain antisense transcripts, which sometimes can hide in a number of 
genomic locations, such as in an intron of a protein coding gene, and will be lost without 
strand information for alignment. Moreover, a number of very recent studies lately have 
suggested that RNAs may form circles after transcription which play a regulatory 
“sponge RNA” like role156–158. These circular RNAs do not have poly-A tails, and will 
thus not be included in poly-A RNA sequencing. Although further investigations are 
needed to support this claim, circular RNAs may in the future also prove to be targetable 
for the treatment of diseases such as emphysema, IPF, and lung cancer. It is technically 
possible to sequence circular RNAs with total RNA sequencing, but the best approach is 
to utilize special enzymes such as RNAseH in library preparation to nick the circularized 
RNA159.  
Furthermore, sequencing of additional sample types would yield additional 
information about disease biology. COPD, IPF, lung cancer, and healthy lung all have 
very different cell types. Thus, it would be helpful to use laser capture microdissection to 
select for only one cell type. Gene expression analysis would be much less likely to be 
confounded when comparing only one cell type, although heat generated during the laser 
capture can selectively degrade some RNAs. Single cell sequencing would also be useful 
in avoiding cell type heterogeneity. 
In the lung cancer space, studies have revealed that tumors are rarely a subclonal 
population, and that there can be heterogeneity within a tumor in terms of presence or 
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absence of a mutation. It is possible that while collecting a sample from a tumor, the area 
sampled may not be an accurate representation of the tumor as a whole. In the future, this 
issue would be best addressed with multiple fine needle biopsies of the tumor, which 
should all undergo transcriptional profiling. By comparing gene expression within the 
tissue, it would be possible to assess the effects of tumor heterogeneity and correct for it 
before comparing tumors or comparing to other non-cancerous tissues.  Lastly, 
sequencing bronchial airway epithelium from patients with and without emphysema, IPF, 
or never smoker lung cancer would provide a tantalizing view into the reaction of the 
airway epithelium to the presence of disease.   
RNA seq data can be analyzed from many different angles, and in this case 
analysis as a whole of the emphysema, IPF, and lung cancer RNAseq data is not 
“complete”. Since analysis was done on seventy-five IPF, COPD, and control samples, 
hundreds more samples from this group have been sequenced. The analysis described in 
this document has yet to be extended into this much larger cohort of samples. The larger 
sample pool is much more powered for analyses such as disease subclass discovery. In 
addition, including more samples empowers us to ask more questions regarding the 
clinical data, such as searching for gene expression changes associated with percent 
emphysema, FEV1/FVC ratio, or other clinical variables. The total pool of lung cancer 
samples sequenced also includes samples from other lung cancer subtypes, including 
squameous cell carcinoma and broncheoalveolar carcinoma. With this larger subset many 
analyses are possible, such as comparing the adjacent normal between smokers with 
adenocarcinoma and smokers with squameous cell carcinoma to determine if the local 
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tumor microenvironment is affected by cancer subtype. Additionally, the lung cancer data 
was only mined for changes in gene expression. To date, no analysis has been done to test 
for never smoker tumor specific changes in splicing.  Since RNA sequencing is an 
unbiased platform, it is also possible to test the data for mutations, such as gene fusions 
and indels. In summary, many future directions remain to be explored both within 
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